Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine
Main Author: | |
---|---|
Publication Date: | 2023 |
Format: | Master thesis |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | http://hdl.handle.net/10773/41121 |
Summary: | Pseudomonas aeruginosa stands out as one of the most challenging pathogens in healthcare settings, namely because of its ability to resist several classes of antibiotics, form biofilms and cause several types of infections such as urinary tract infections. In this sense, new alternatives to conventional antimicrobials are needed. Phage therapy emerges as a promising alternative to antibiotics. This therapy involves the use of bacteriophages (also called phages), viruses that specifically infect and kill bacteria. In this study, 3 different phages (phPA-G, phPA-Intesti and phPA-Pyo) were used, alone or in a cocktail, to inactivate a P. aeruginosa strain. Planktonic bacteria assays were carried out in Tryptic Soy Broth (TSB), at 37 °C at multiplicity of infection (MOI, the ratio between the number of phages and bacteria) of 1, 10 and 100. The most effective phage against the planktonic bacteria was then selected to destroy P. aeruginosa biofilms, and to test the combined action of the phage and an antibiotic (ciprofloxacin). The results demonstrated that the most effective phage against the planktonic bacteria was phPA-Intesti, with a maximum reduction of around 4 log colony forming units (CFU)/mL, after 8 h (MOI of 1). On the P. aeruginosa biofilm assays, phPA-Intesti demonstrated to be more efficient than ciprofloxacin, with a bacterial biofilm reduction of 5 log CFU/mL, after 4 h. The ciprofloxacin caused a bacterial biofilm reduction of 4 log CFU/mL, after 4 h. The combination of phage and antibiotic did not improve the biofilm inactivation. The phage phPA-Intesti has been shown to be effective against P. aeruginosa biofilms with even better results than those obtained with the antibiotic. In a world, where antibiotic resistance is a serious public health problem, phage therapy reappears as a viable alternative to antibiotics. |
id |
RCAP_eeee76e9e74a687e7f0a1140699c29fc |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/41121 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urinePseudomonas aeruginosaMulti-drug resistant bacteriaPhagesPhage therapyBiofilmAntibioticsPseudomonas aeruginosa stands out as one of the most challenging pathogens in healthcare settings, namely because of its ability to resist several classes of antibiotics, form biofilms and cause several types of infections such as urinary tract infections. In this sense, new alternatives to conventional antimicrobials are needed. Phage therapy emerges as a promising alternative to antibiotics. This therapy involves the use of bacteriophages (also called phages), viruses that specifically infect and kill bacteria. In this study, 3 different phages (phPA-G, phPA-Intesti and phPA-Pyo) were used, alone or in a cocktail, to inactivate a P. aeruginosa strain. Planktonic bacteria assays were carried out in Tryptic Soy Broth (TSB), at 37 °C at multiplicity of infection (MOI, the ratio between the number of phages and bacteria) of 1, 10 and 100. The most effective phage against the planktonic bacteria was then selected to destroy P. aeruginosa biofilms, and to test the combined action of the phage and an antibiotic (ciprofloxacin). The results demonstrated that the most effective phage against the planktonic bacteria was phPA-Intesti, with a maximum reduction of around 4 log colony forming units (CFU)/mL, after 8 h (MOI of 1). On the P. aeruginosa biofilm assays, phPA-Intesti demonstrated to be more efficient than ciprofloxacin, with a bacterial biofilm reduction of 5 log CFU/mL, after 4 h. The ciprofloxacin caused a bacterial biofilm reduction of 4 log CFU/mL, after 4 h. The combination of phage and antibiotic did not improve the biofilm inactivation. The phage phPA-Intesti has been shown to be effective against P. aeruginosa biofilms with even better results than those obtained with the antibiotic. In a world, where antibiotic resistance is a serious public health problem, phage therapy reappears as a viable alternative to antibiotics.Pseudomonas aeruginosa destaca-se como um dos principais agentes patogénicos em ambientes hospitalares, nomeadamente devido à sua capacidade de resistir a diversos antibióticos, formar biofilmes e causar diversos tipos de infeções, como infeções do trato urinário. Neste sentido, são necessárias novas alternativas aos antimicrobianos convencionais. A terapia fágica surge como uma alternativa promissora aos antibióticos. Esta terapia envolve o uso de bacteriófagos (também denominados de fagos), vírus que infetam e matam bactérias. Neste estudo, foram utilizados 3 fagos diferentes (phPA-G, phPA-Intesti e phPA-Pyo), sozinhos ou em cocktail, para inativar uma estirpe multirresistente de P. aeruginosa. Ensaios com bactérias planctónicas foram realizados em Tryptic Soy Broth (TSB), a 37 °C com multiplicidade de infeção (MOI, razão entre o número de fagos e bactérias) de 1, 10 e 100. O fago mais eficaz foi selecionado para destruir biofilmes de P.aeruginosa e para testar a ação combinada do fago e de um antibiótico (ciprofloxacina). Os resultados demonstraram que o fago mais eficaz contra as bactérias planctónicas foi o phPA-Intesti, que causou uma redução máxima de cerca de 4 log de unidades formadoras de colónias (UFC)/mL, após 8 h (MOI de 1). Nos ensaios com biofilmes o phPA-Intesti demonstrou ser mais eficiente que a ciprofloxacina, causando uma redução das bactérias do biofilme de 5 log UFC/mL, após 4 h. A ciprofloxacina causou uma redução de 4 log UFC/mL, após 4 h. A combinação de fago e antibiótico não melhorou a inativação das bactérias do biofilme. O fago phPA-Intesti demonstrou ser eficaz na destruição dos biofilmes de P. aeruginosa, com resultados ainda melhores do que aqueles obtidos com o antibiótico. Num mundo onde a resistência aos antibióticos é um grave problema de saúde pública, a terapia fágica reemerge como uma alternativa viável aos antibióticos.2025-12-20T00:00:00Z2023-12-12T00:00:00Z2023-12-12info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10773/41121engMartinho, Inês Mónicainfo:eu-repo/semantics/embargoedAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-06T04:53:26Zoai:ria.ua.pt:10773/41121Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T14:23:48.720650Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
title |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
spellingShingle |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine Martinho, Inês Mónica Pseudomonas aeruginosa Multi-drug resistant bacteria Phages Phage therapy Biofilm Antibiotics |
title_short |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
title_full |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
title_fullStr |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
title_full_unstemmed |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
title_sort |
Phage therapy in the destruction of Pseudomonas aeruginosa biofilms in urine |
author |
Martinho, Inês Mónica |
author_facet |
Martinho, Inês Mónica |
author_role |
author |
dc.contributor.author.fl_str_mv |
Martinho, Inês Mónica |
dc.subject.por.fl_str_mv |
Pseudomonas aeruginosa Multi-drug resistant bacteria Phages Phage therapy Biofilm Antibiotics |
topic |
Pseudomonas aeruginosa Multi-drug resistant bacteria Phages Phage therapy Biofilm Antibiotics |
description |
Pseudomonas aeruginosa stands out as one of the most challenging pathogens in healthcare settings, namely because of its ability to resist several classes of antibiotics, form biofilms and cause several types of infections such as urinary tract infections. In this sense, new alternatives to conventional antimicrobials are needed. Phage therapy emerges as a promising alternative to antibiotics. This therapy involves the use of bacteriophages (also called phages), viruses that specifically infect and kill bacteria. In this study, 3 different phages (phPA-G, phPA-Intesti and phPA-Pyo) were used, alone or in a cocktail, to inactivate a P. aeruginosa strain. Planktonic bacteria assays were carried out in Tryptic Soy Broth (TSB), at 37 °C at multiplicity of infection (MOI, the ratio between the number of phages and bacteria) of 1, 10 and 100. The most effective phage against the planktonic bacteria was then selected to destroy P. aeruginosa biofilms, and to test the combined action of the phage and an antibiotic (ciprofloxacin). The results demonstrated that the most effective phage against the planktonic bacteria was phPA-Intesti, with a maximum reduction of around 4 log colony forming units (CFU)/mL, after 8 h (MOI of 1). On the P. aeruginosa biofilm assays, phPA-Intesti demonstrated to be more efficient than ciprofloxacin, with a bacterial biofilm reduction of 5 log CFU/mL, after 4 h. The ciprofloxacin caused a bacterial biofilm reduction of 4 log CFU/mL, after 4 h. The combination of phage and antibiotic did not improve the biofilm inactivation. The phage phPA-Intesti has been shown to be effective against P. aeruginosa biofilms with even better results than those obtained with the antibiotic. In a world, where antibiotic resistance is a serious public health problem, phage therapy reappears as a viable alternative to antibiotics. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-12-12T00:00:00Z 2023-12-12 2025-12-20T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/41121 |
url |
http://hdl.handle.net/10773/41121 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833594557540859904 |